These top 10 drug companies, account for over 60 per cent of the industry’s combined net worth and over half of the assets. They accounted for only 43 per cent of the industry’s borrowings in 2012-13 and 27 per cent of the industry’s interest outgo during 2013, as per the report from Business Standard.
PrintWeek India looks at the sales and market share of the top whales from the Indian pharmaceutical industry,
With its recent take-over of Ranbaxy, Sun Pharma leads the Indian pharma market with a market valuation of Rs 1,30,029.9 crore and a net profit of Rs 4,770.1 crore. Today it is the largest chronic prescription company in India and a market leader in psychiatry, neurology, cardiology, orthopedics, ophthalmology, gastroenterology and nephrology.
Manufacturing facilities of the company are located at Jammu, Sikkim, four sites in Gujarat, Silvasa, Dadra Nagar and Haveli, Ahmednagar and Tamil Nadu. The company offers formulations and active ingredients in various therapeutic areas.
Dr Reddy’s Laboratories
Dr Reddy’s Laboratories' market capitalisation accounts to Rs 44,573.9 crore with a net profit of Rs 2240.5 crore. Manufacturing over 190 drug medications, the company’s plants are located in Hyderabad, UK and Netherlands. The top drugs in its roster are Omez, Nise neumoslide, Stamlo, Enam, Atocor, and Razo, to name a few.
Lupin Pharma is valued at a market capitalisation of Rs 43,669.6 crore with a net profit of Rs 1691.5 crore. With nine manufacturing facilities located at Aurangabad, Ankleshwar, Mandideep, Tarapur, Goa, Jammu, Vadodara, Indore and Nagpur, the company’s key drugs include Combutol, Combunex, Pyzinakid, Cyclorin, Lup-INH, Lupituss and Thrilpil, to name a few.
The IRF (Indian Regional Formulation) business contributed 25% of the company’s overall revenues for FY 2012-13, growing by 24%.
Cipla’s market valuation stands at Rs 32,116.0 crore with a net profit of Rs 1,379.3 crore. Cipla has 34 manufacturing units in eight locations across India and has presence in 170 countries. Cipla makes drugs to treat cardiovascular disease, arthritis, diabetes, weight control, depression and many other health conditions. Cipla has over 2000 products in 65 therapeutic categories available in over 40 dosage forms.
Its key products include the following drugs, Escitalopram (anti-depressant), Lamivudine, Fluticasone propionate.
GlaxoSmithKline(GSK) Pharma is the world’s fourth largest pharmaceutical company after Pfizer, Novartis and Sanofi. The company’s market capitalisation stands at Rs 21,539.6 crore adding a net profit of Rs 484.4 crore. The company has its R&D sites in Thane and Nasik, Maharashtra.
GSK produces and sells a wide range of prescription-only and over-the-counter products, including drinks and toothpastes. Its top-selling prescription drugs include Paxi, Avanda, Wellbutrin, Advair, Flovent, Ventolin and Zantac. Other top products include Sensodyne and Horlicks, to name a few.
This Ahmedabad-based pharmaceutical company is a significant manufacturer of generic drugs. With a market capitalisation of Rs 20,563.1 crore at a net profit of Rs 829.7 crore, the company ranks as the fifth largest pharmaceutical company in India.
From nine pharmaceutical production operations in India at Ankleshwar, Vadodara, Patalganga, Navi Mumbai, Goa, Baddi, Sikkim, Dabhasa and Vatva, Zydus Cadila develops and manufactures a large range of pharmaceuticals as well as diagnostics, herbal, skin care and other OTC products.
With a valuation of Rs 18,041.4 crore the company generated a net profit of Rs 780.5 crore, a considerable increase from its previous year’s Rs 598.6 crore profit. The company’s manufacturing facilities are located at Hyderabad and Vishakapatnam, both of which are primarily engaged in Active Pharmaceutical Ingredients (APIs) and intermediates for generics and custom synthesis of customer’s own discovery product.
Headquarted in Hyderabad, the company manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company reported a net market capitalisation of Rs 16,433.3 crore with a net profit of Rs 779.7 crore.
With six key formulation facilities in India and one each in Brazil and US the company exports to over 125 countries across the globe with more than 70% of its revenues derived out of international operations.
Glenmark Pharma, headquartered in Mumbai, is a leading player in the dermatology segment. The market capitalisation stands at Rs 15,801.5 crore registering a net profit of Rs 666 crore. The India business contributes over 25% to the overall sales of the group. With manufacturing facilities at Nasik, Baddi, Nalagarh, Sikkim, Czech and Brazil, the company markets around 350 products in India.